^
    16h
    CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Baylor College of Medicine | Trial completion date: Jul 2026 --> Jul 2027
    Trial completion date
    16h
    A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant (clinicaltrials.gov)
    P1, N=46, Recruiting, City of Hope Medical Center | Trial completion date: Feb 2030 --> May 2028 | Trial primary completion date: Feb 2030 --> May 2028
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Triplex (CMV-MVA vaccine)
    17h
    Pharmacogenomic impact and genetic architecture of toxicity in pediatric acute lymphoblastic leukemia induction therapy: an exploratory modeling approach. (PubMed, Front Pharmacol)
    The integration of alternative genotype parameterizations and regularized machine learning highlights pathways for future predictive research. However, given the retrospective nature of the study and inherent risks of internal optimism, these scores serve as biologically informed proof-of-concept models that strictly require robust prospective external validation.
    Journal
    |
    CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5)
    17h
    CD19-negative relapse with an apparent cytogenetic shift after blinatumomab-induced measurable residual disease clearance in Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. (PubMed, Leuk Res Rep)
    Blinatumomab was administered after one cycle of high-dose methotrexate/cytarabine, resulting in MRD negativity after one cycle...Inotuzumab ozogamicin induced a second hematological remission with MRD negativity, although disease control was not durable. This case highlights the importance of repeat immunophenotypic and cytogenetic assessment at relapse after blinatumomab treatment.
    Journal
    |
    CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    cytarabine • Blincyto (blinatumomab) • methotrexate • Besponsa (inotuzumab ozogamicin) • methotrexate IV
    17h
    FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia. (PubMed, Leukemia)
    Using B-ALL cell lines and patient-derived xenografts, we show that FATP2-expressing TP53-mutant B-ALL resistance to CAR-T is dependent on exogenous lipid uptake to fuel fatty acid oxidation (FAO) and cell survival, which can be pharmacologically targeted through inhibition of neutral lipolysis and CPT1. These findings identify FATP2-mediated fatty acid uptake and downstream FAO as a potential target to improve existing CAR-T efficacy in human B-ALL.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • CD19 (CD19 Molecule)
    |
    TP53 mutation • TP53 wild-type
    18h
    A Large Concept Model for Mechanistic Simulation of Disease Trajectories: A Hypothesis-Generating Exemplar for Pediatric Acute Lymphoblastic Leukemia. (PubMed, Comput Struct Biotechnol J)
    Greater relapse-associated biological divergence was observed in selected genotype-age strata, particularly in domains related to clonal evolution, treatment resistance, and minimal residual disease. This ALL-focused proof of concept demonstrates the architectural and analytic potential of mechanistic trajectory simulation for hypothesis generation, longitudinal systems modeling, and future integration with real-world longitudinal datasets.
    Journal
    |
    RUNX1 (RUNX Family Transcription Factor 1) • ETV6 (ETS Variant Transcription Factor 6)
    18h
    Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies (clinicaltrials.gov)
    P1, N=48, Recruiting, Sawa Ito, MD | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BCL2 (B-cell CLL/lymphoma 2) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • fludarabine IV • thiotepa • busulfan
    20h
    NCI-2014-00639: Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML (clinicaltrials.gov)
    P2, N=108, Active, not recruiting, City of Hope Medical Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • etoposide IV
    20h
    Relapse Thresholds (12/24 Mo) Define Survival Disparity in Pediatric B-ALL. (PubMed, Am J Hematol)
    These findings support POD12 and POD24 as clinically practical, data-driven landmarks for identifying patients with adverse survival outcomes. They may also inform the exploratory evaluation of 1-year and 2-year progression-free survival as hypothesis-generating candidate early trial endpoints, pending prospective validation.
    Journal
    |
    KMT2A (Lysine Methyltransferase 2A) • PBX1 (PBX Homeobox 1)
    |
    MLL rearrangement
    20h
    Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients (clinicaltrials.gov)
    P1/2, N=91, Recruiting, Curocell Inc. | Trial completion date: Feb 2028 --> Sep 2030 | Trial primary completion date: May 2023 --> Aug 2030
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV • Rimqarto (anbalcabtagene autoleucel)
    23h
    A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma (clinicaltrials.gov)
    P1/2, N=18, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P1/2 trial
    |
    CD5 (CD5 Molecule)
    |
    fludarabine IV